Drug Details
| General Information of the Drug (ID: DR5354) | ||||
|---|---|---|---|---|
| Name |
Triptorelin
|
|||
| Synonyms |
TRIPTORELIN; 57773-63-4; Triptoreline; Decapeptyl; (D-Trp6)-GnRH; Triptorelina; Triptorelinum; Trelstar; Triptodur; Diphereline; (6-D-Tryptophan)luteinizing hormone-releasing hormone; CL 118532; CL-118532; pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2; AY-25650; Luteinizing hormone-releasing factor (pig), 6-D-tryptophan; CL 118,532; CHEBI:63633; Pamorelin; Trelstar depot; 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide; Trelstar LA; Arvekap; Diferelin; Luteinizing hormone-releasing factor (swine), 6-D-tryptophan-; UNII-08AN7WA2G0; 08AN7WA2G0; D-Tryptophan-LH-RH; Wy 42462; Triptoreline [INN-French]; Triptorelinum [INN-Latin]; Triptorelina [INN-Spanish]; AY 25650; Salvacyl; Trellasar; Moapar; Triptorelin [USAN:INN:BAN]; Decapeptyl SR; Pamorelin LA; UNII-9081Y98W2V; Triptorelin (swine); BIM 21003; Wy 42422; Wy-42462; D-Trp6-LHRH; Debio-8206; Triptorelin (USAN/INN); (D-Trp6)-LH-RH; GTPL1177; SCHEMBL5079698; CHEMBL1201334; SCHEMBL22289009; HMS2090C17; EX-A3857; BIM-21003; AKOS030213249; 9081Y98W2V; CS-5745; DB06825; NCGC00167301-01; NCGC00167301-02; AK552887; AS-71149; BN-52014; HY-12551; 73T634; D06247; [D-Trp6]-LH-RH, >=97% (HPLC), powder; AB01275488-01; pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-GlyNH2; Q1992452; (S)-1-((3S,6S,9S,12S,15R,18S,21S)-3-((1H-imidazol-5-yl)methyl)-6,15-bis((1H-indol-3-yl)methyl)-21-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9-(hydroxymethyl)-18-isobutyl-1,4,7,10,13,16,19-heptaoxo-1-((S)-5-oxopyrrolidin-2-yl)-2,5,8,11,14,17,20-heptaazadocosan-22-oyl)-N-(2-amino-2-oxoethyl)pyrrolidine-2-carboxamide
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C64H82N18O13
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8
|
|||
| InChI |
1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1
|
|||
| InChIKey |
VXKHXGOKWPXYNA-PGBVPBMZSA-N
|
|||
| CAS Number |
CAS 57773-63-4
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Exemestane | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | Ascites OT (5*106) cells were intraperitoneally transplanted in female Wistar rats. | |||||
| Experimental
Result(s) |
Triptorelin and exemestane increase antitumor activity of cisplatin in respect to the transplantable malignant ascites OT and significantly increase survival of animals, especially when triptorelin and cisplatin are used in combination. | |||||
